Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/107479
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcFarlane, A.en
dc.contributor.authorLawrence-Wood, E.en
dc.contributor.authorVan Hooff, M.en
dc.contributor.authorMalhi, G.en
dc.contributor.authorYehuda, R.en
dc.date.issued2017en
dc.identifier.citationCurrent Psychiatry Reports, 2017; 19(2):10-1-10-9en
dc.identifier.issn1523-3812en
dc.identifier.issn1535-1645en
dc.identifier.urihttp://hdl.handle.net/2440/107479-
dc.descriptionPublished online: 7 February 2017en
dc.description.abstractDespite the substantial body of neurobiological research, no specific drug target has been developed to treat PTSD and there are substantial limitations with the available interventions. We propose that advances are likely to depend on the development of better classification of the heterogeneity of PTSD using a staging approach of disease. A primary rationale for staging is to highlight the probability that distinct therapeutic approaches need to be utilised according to the degree of biological progression of the disorder. Prospective studies, particularly of military populations, provide substantial evidence about the emerging biological abnormalities that precede the full-blown disorder. These need to be targeted with tailored interventions to prevent disease progression. Equally, the neurobiology of chronic unremitting PTSD needs to be differentiated from the acute disorder which emerges across a spectrum of severity, and this range of presentations correspondingly needs to be addressed with differing therapeutic strategies. The staging approach also needs to take account of the range of somatic pathological outcomes that are being identified as a consequence of traumatic stress exposure. PTSD should be conceptualised as a systemic disorder underpinned a range of biological dysregulation, including metabolic and altered immune function, reflected in the increased rates of cardiovascular and autoimmune disease. The effectiveness of novel treatments needs to be judged across their effectiveness in addressing the spectrum of trauma-related pathology.en
dc.description.statementofresponsibilityAlexander Cowell McFarlane, Eleanor Lawrence-Wood, Miranda Van Hooff, Gin S. Malhi, Rachel Yehudaen
dc.language.isoenen
dc.publisherSpringer USen
dc.rights© Springer Science+Business Media New Yorken
dc.subjectPTSD; Staging; Subsyndromal; Neurobiology; Inflammation; Medical comorbidity; Duration of illness; Longitudinal course; Delayed onset; Treatmenten
dc.titleThe need to take a staging approach to the biological mechanisms of PTSD and its treatmenten
dc.typeJournal articleen
dc.identifier.rmid0030064703en
dc.identifier.doi10.1007/s11920-017-0761-2en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/568970en
dc.identifier.pubid287337-
pubs.library.collectionPsychiatry publicationsen
pubs.library.teamDS03en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidLawrence-Wood, E. [0000-0003-4643-6232]en
dc.identifier.orcidVan Hooff, M. [0000-0002-9376-3714]en
Appears in Collections:Psychiatry publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.